Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/2/2020
SIETES contiene 92902 citas

 
 
 1 a 20 de 141 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Sultana J, Moretti U, Addis A, Caduff P, Capuano A, Kant A, Laporte JR, Lindquist M, Raine J, Sartori D, Trifirò G, Tuccori M, Venegoni M, van Puijenbroek E, Leone R. Workshop on the Italian pharmacovigilance system in the international context: critical issues and perspectives. Drug Saf 2019;42:mayo. [Ref.ID 103115]
2. Cita con resumen
Ortiz de Landaluce L, Carbonell P, Asensio C, Escoda N, López P, Laporte JR. Gabapentin and pregabalin and risk of atrial fibrillation in the elderly: a population-based cohort study in an electronic prescription database. Drug Saf 2018;41:diciembre. [Ref.ID 102913]
3.Enlace a cita original Cita con resumen
Asensio C, Escoda N, Sabaté M, Carbonell P, López P, Laporte JR. Prevalence of use of antipsychotic drugs in the elderly in Catalonia. Eur J Clin Pharmacol 2018;74:septiembre. [Ref.ID 102828]
4.Enlace a cita original Cita con resumen
Laporte JR. Fifty years of pharmacovigilance - Medicines safety and public health. Pharmacoepidemiol Drug Saf 2016;25:junio. [Ref.ID 99974]
5.Enlace a cita original
Ferrer P, Rafaniello C, Sabaté M, Ballarín E, Coma A, Zara C, Capuano A, Rossi F, Laporte JR, Ibáñez L. Cross-national comparison of antiepileptic drug use: Catalonia, Denmark and Norway, 2007-2011. Epidemiology Biostatistics and Public Health 2014;11:e9405-9409. [Ref.ID 98375]
6. Cita con resumen
Laporte JR, Bosch M. Re: Meta-analysis of side effects of statins shows need for trial transparency. BMJ 2014:2 de mayo. [Ref.ID 98148]
7.Enlace a cita original Cita con resumen
Sabaté M, Pacheco JF, Ballarín E, Ferrer P, Petri H, Hasford J, Schoonen MW, Rottenkolber M, Fortuny J, Laporte JR, Ibáñez L, on behalf of the PROTECT work package 2. A compilation of research working groups on drug utilisation across Europe. BMC Research Notes 2014;7:143. [Ref.ID 97264]
8. Cita con resumen
Agustí A, Pagès E, Cuxart A, Ballarín E, Vidal X, Teixidor J, Tomás J, Villar MM, Laporte JR. Exposure to medicines among patients admitted for hip fracture and the case-fatality rate at 1 year: a longitudinal study. Eur J Clin Pharmacol 2012;68:1525-31. [Ref.ID 93962]
9.Enlace a cita original
Llop R, Bosch M, Figueras A, Laporte JR. Separating the wheat from the chaff: essential information in therapeutics. Eur J Clin Pharmacol 2012;68:abril. [Ref.ID 92598]
10. Cita con resumen
Théophile H, Laporte JR, Moore N, Martin K-L, Bégaud B. The case-population study design: an analysis of its application in pharmacovigilance. Drug Saf 2011;34:861-8. [Ref.ID 91174]
11.Enlace a cita original
Sabaté M, Ibáñez L, Pérez E, Vidal X, Buti M, Xiol X, Mas A, Guarner C, Forné M, Solà R, Castellote J, Rigau J, Laporte JR. Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series. BMC Gastroenterology 2011;11:80. [Ref.ID 91075]
12.Enlace a cita original
Laporte JR, Llop R, Bosch M. Avenços que canvien la pràctica clínica. Annals Med (Barc) 2011;94:S3-S10. [Ref.ID 90417]
13.Enlace a cita original
Duran M, Pérez E, Abanades S, Vidal X, Saura C, Majem M, Arriola E, Rabanal M, Pastor A, Farré M, Rams N, Laporte JR, Capellà D. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 2010;70:656-63. [Ref.ID 89567]
14. Cita con resumen
Laporte JR. Pour une pharmacovigilance plus ambitieuse. Prescrire 2010;30:391-3. [Ref.ID 88457]
15. Cita con resumen
Laporte JR, Ibáñez L, Vendrell L, Ballarín E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. [Ref.ID 87996]
16. Cita con resumen
Laporte JR. La responsabilitat del prescriptor i del sistema de salut per treure benefici de l'ús de medicaments. Butlletí Farmacoterapèutic Hospital de Santa Maria 2008;12:1. [Ref.ID 85904]
17. Cita con resumen
Ibáñez L, Vidal X, Laporte JR. Proton pump inhibitors and risk of upper gastrointestinal bleeding in NSAID users. Am J Gastroenterol 2008;103:2658-1659. [Ref.ID 84102]
18.
Beard K, Egberts T, Hallas J, Hasford J, Laporte JR, Moore N, Shakir S, Sturkenboom M. European commission consultation on pharmacovigilance. Pharmacoepidemiol Drug Saf 2008;17:108-9. [Ref.ID 82284]
19.Tiene citas relacionadas Cita con resumen
Ibáñez L, Vidal X, Laporte JR. Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2008;148:319-20. [Ref.ID 82254]
20. Cita con resumen
Vidal X, Ibáñez L, Vendrell L, Conforti A, Laporte JR, on behalf of the Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study. Drug Saf 2008;31:159-68. [Ref.ID 82244]
Seleccionar todas
 
 1 a 20 de 141 siguiente >>